Amgen Valuation Debate Intensifies After Strong Q2 Results and Raised Guidance

Key Facts

1Amgen reported strong Q2 2026 results and raised its full-year guidance.

2Valuation models conflict, with a DCF model estimating fair value at $654.75 while another suggests the stock is 15.6% overvalued.

Following a period of sector-wide anticipation, Amgen reported strong Q2 2026 financial results and subsequently raised its full-year guidance. According to reports, this robust performance has triggered a significant debate among analysts regarding the stock's intrinsic value. While a discounted cash flow (DCF) model estimates the fair value at $654.75, alternative assessments suggest the stock is currently 15.6% overvalued.

The valuation conflict emerges amid strong price momentum, with the stock delivering a 15.46% return over the past month and a 27.02% return year-to-date per analyst data. The bullish case frames the company as undervalued relative to its long-term cash flows, whereas the bearish narrative sets a fair value of $359.98, implying that the recent price surge may have outpaced fundamental justifications.

At the close of August 10, 2026, AMGN was priced at $417.2, having traded between a day low of $406.42 and a high of $417.36. In the absence of upcoming sector-specific catalysts in the economic calendar, traders will likely focus on whether the stock can maintain its position above recent support levels established during the August 10 session.

Sources:

Simply Wall Street